Global Pharmacovigilance research

Pharmacovigilance Comprehensive Study by End User (Hospitals, Research Organizations, Others), Service Provider (In-house, Contract Outsourcing), Pharmacovigilance Methods (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining) Players and Region - Global Market Outlook to 2032

Pharmacovigilance Market by XX Submarkets | Forecast Years 2025-2032 | CAGR: 12.18%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Pharmacovigilance
Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. Increasing number of patients with chronic diseases led to rise in demand of novel drugs and treatment. For instance, According to World Health Organization (WHO) 2018 report, cardiovascular diseases accounted for nearly 836,546 deaths in the United States and 3.9 million deaths in Europe. And cancer cause of death and led to 9.6 million deaths globally in 2018. Further, technological advancement such as emergence of drug safety and pharmacovigilance software expected to drive the pharmacovigilance market over the forecasted period.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)
CAGR12.18%


Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Pharmacovigilance market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

ArisGlobal (United States), Ennov Solutions Inc. (United States), EXTEDO GmbH (United States), Novartis (Switzerland), PARAXEL (United States), MAKROCARE (India), Online Business Applications, Inc. (United States), United BioSource Corporation (United States), Cmed Group (United Kingdom) and Medpace (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sarjen Systems Pvt. Ltd (India), Sparta Systems, Inc. (United States) and Covance (United States).

Segmentation Overview
AMA Research has segmented the market of Global Pharmacovigilance market by and Region.



On the basis of geography, the market of Pharmacovigilance has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User , the sub-segment i.e. Hospitals will boost the Pharmacovigilance market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Service Provider , the sub-segment i.e. In-house will boost the Pharmacovigilance market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Pharmacovigilance Methods , the sub-segment i.e. Spontaneous Reporting will boost the Pharmacovigilance market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emergence of Drug Safety and Pharmacovigilance Software and Increasing Investments in Pharmaceutical R&D in Developing Economies

Market Growth Drivers:
Increasing Government Initiatives for Drug Safety Regulations and Technological Advancement in Pharmacovigilance Owing to Rise in Health Information Functionality

Challenges:
Lack of Advanced Healthcare Infrastructure in the Emerging Economies

Restraints:
High Cost Associated with Pharmacovigilance Services

Opportunities:
Growing Adoption of Pharmacovigilance Software by Contract Research Organizations and Increasing Demand for Pharmacovigilance Software from Developing Countries


“According to Good Pharmacovigilance Practices a set of measures which were developed to facilitate the performance of pharmacovigilance in the EU. The legal basis for pharmacovigilance for medicines for human use in the EU is laid down in Directive 2001/83/EC and Regulation (EC) No 726/2004, as amended. The most recent amendments to this legislation in 2010 were implemented to further protect public health by strengthening the European-wide system for monitoring the safety of medicines. The legislation is accompanied by the implementing regulation which was published by the European Commission in June 2012. Implementing Regulation (EU) No 520/2012 provides details on some of the operational aspects for the revised legislation. In addition, detailed guidance in the form of a number of good pharmacovigilance practice (GVP) modules to facilitate the performance of pharmacovigilance in the European Union (EU).”

Key Target Audience
Pharma and Biotech Companies, Contract Research Organizations (CROs), Business Process Outsourcing (BPO) Firms, Other Pharmacovigilance Service Providers, Government Agencies, Research Institute, Market Research Firms and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By End User
  • Hospitals
  • Research Organizations
  • Others

By Service Provider
  • In-house
  • Contract Outsourcing

By Pharmacovigilance Methods
  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Government Initiatives for Drug Safety Regulations
      • 3.2.2. Technological Advancement in Pharmacovigilance Owing to Rise in Health Information Functionality
    • 3.3. Market Challenges
      • 3.3.1. Lack of Advanced Healthcare Infrastructure in the Emerging Economies
    • 3.4. Market Trends
      • 3.4.1. Emergence of Drug Safety and Pharmacovigilance Software
      • 3.4.2. Increasing Investments in Pharmaceutical R&D in Developing Economies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pharmacovigilance, by End User , Service Provider , Pharmacovigilance Methods and Region (value) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global Pharmacovigilance (Value)
      • 5.2.1. Global Pharmacovigilance Region
        • 5.2.1.1. South America
          • 5.2.1.1.1. Brazil
          • 5.2.1.1.2. Argentina
          • 5.2.1.1.3. Rest of South America
        • 5.2.1.2. Asia Pacific
          • 5.2.1.2.1. China
          • 5.2.1.2.2. Japan
          • 5.2.1.2.3. India
          • 5.2.1.2.4. South Korea
          • 5.2.1.2.5. Taiwan
          • 5.2.1.2.6. Australia
          • 5.2.1.2.7. Rest of Asia-Pacific
        • 5.2.1.3. Europe
          • 5.2.1.3.1. Germany
          • 5.2.1.3.2. France
          • 5.2.1.3.3. Italy
          • 5.2.1.3.4. United Kingdom
          • 5.2.1.3.5. Netherlands
          • 5.2.1.3.6. Rest of Europe
        • 5.2.1.4. MEA
          • 5.2.1.4.1. Middle East
          • 5.2.1.4.2. Africa
        • 5.2.1.5. North America
          • 5.2.1.5.1. United States
          • 5.2.1.5.2. Canada
          • 5.2.1.5.3. Mexico
  • 6. Pharmacovigilance: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ArisGlobal (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Ennov Solutions Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. EXTEDO GmbH (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. PARAXEL (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MAKROCARE (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Online Business Applications, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. United BioSource Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cmed Group (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Medpace (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pharmacovigilance Sale, by End User , Service Provider , Pharmacovigilance Methods and Region (value) (2027-2032)
    • 7.1. Introduction
    • 7.2. Global Pharmacovigilance (Value)
      • 7.2.1. Global Pharmacovigilance Region
        • 7.2.1.1. South America
          • 7.2.1.1.1. Brazil
          • 7.2.1.1.2. Argentina
          • 7.2.1.1.3. Rest of South America
        • 7.2.1.2. Asia Pacific
          • 7.2.1.2.1. China
          • 7.2.1.2.2. Japan
          • 7.2.1.2.3. India
          • 7.2.1.2.4. South Korea
          • 7.2.1.2.5. Taiwan
          • 7.2.1.2.6. Australia
          • 7.2.1.2.7. Rest of Asia-Pacific
        • 7.2.1.3. Europe
          • 7.2.1.3.1. Germany
          • 7.2.1.3.2. France
          • 7.2.1.3.3. Italy
          • 7.2.1.3.4. United Kingdom
          • 7.2.1.3.5. Netherlands
          • 7.2.1.3.6. Rest of Europe
        • 7.2.1.4. MEA
          • 7.2.1.4.1. Middle East
          • 7.2.1.4.2. Africa
        • 7.2.1.5. North America
          • 7.2.1.5.1. United States
          • 7.2.1.5.2. Canada
          • 7.2.1.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. South America Pharmacovigilance, by Country USD Million (2019-2024)
  • Table 2. South America Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 3. South America Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 4. South America Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 5. Brazil Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 6. Brazil Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 7. Brazil Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 8. Argentina Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 9. Argentina Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 10. Argentina Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 11. Rest of South America Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 12. Rest of South America Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 13. Rest of South America Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 14. Asia Pacific Pharmacovigilance, by Country USD Million (2019-2024)
  • Table 15. Asia Pacific Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 16. Asia Pacific Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 17. Asia Pacific Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 18. China Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 19. China Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 20. China Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 21. Japan Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 22. Japan Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 23. Japan Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 24. India Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 25. India Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 26. India Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 27. South Korea Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 28. South Korea Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 29. South Korea Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 30. Taiwan Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 31. Taiwan Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 32. Taiwan Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 33. Australia Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 34. Australia Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 35. Australia Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 36. Rest of Asia-Pacific Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 37. Rest of Asia-Pacific Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 38. Rest of Asia-Pacific Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 39. Europe Pharmacovigilance, by Country USD Million (2019-2024)
  • Table 40. Europe Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 41. Europe Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 42. Europe Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 43. Germany Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 44. Germany Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 45. Germany Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 46. France Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 47. France Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 48. France Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 49. Italy Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 50. Italy Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 51. Italy Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 52. United Kingdom Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 53. United Kingdom Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 54. United Kingdom Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 55. Netherlands Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 56. Netherlands Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 57. Netherlands Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 58. Rest of Europe Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 59. Rest of Europe Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 60. Rest of Europe Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 61. MEA Pharmacovigilance, by Country USD Million (2019-2024)
  • Table 62. MEA Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 63. MEA Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 64. MEA Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 65. Middle East Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 66. Middle East Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 67. Middle East Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 68. Africa Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 69. Africa Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 70. Africa Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 71. North America Pharmacovigilance, by Country USD Million (2019-2024)
  • Table 72. North America Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 73. North America Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 74. North America Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 75. United States Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 76. United States Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 77. United States Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 78. Canada Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 79. Canada Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 80. Canada Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 81. Mexico Pharmacovigilance, by End User USD Million (2019-2024)
  • Table 82. Mexico Pharmacovigilance, by Service Provider USD Million (2019-2024)
  • Table 83. Mexico Pharmacovigilance, by Pharmacovigilance Methods USD Million (2019-2024)
  • Table 84. Company Basic Information, Sales Area and Its Competitors
  • Table 85. Company Basic Information, Sales Area and Its Competitors
  • Table 86. Company Basic Information, Sales Area and Its Competitors
  • Table 87. Company Basic Information, Sales Area and Its Competitors
  • Table 88. Company Basic Information, Sales Area and Its Competitors
  • Table 89. Company Basic Information, Sales Area and Its Competitors
  • Table 90. Company Basic Information, Sales Area and Its Competitors
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. South America Pharmacovigilance, by Country USD Million (2027-2032)
  • Table 95. South America Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 96. South America Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 97. South America Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 98. Brazil Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 99. Brazil Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 100. Brazil Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 101. Argentina Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 102. Argentina Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 103. Argentina Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 104. Rest of South America Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 105. Rest of South America Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 106. Rest of South America Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 107. Asia Pacific Pharmacovigilance, by Country USD Million (2027-2032)
  • Table 108. Asia Pacific Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 109. Asia Pacific Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 110. Asia Pacific Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 111. China Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 112. China Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 113. China Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 114. Japan Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 115. Japan Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 116. Japan Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 117. India Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 118. India Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 119. India Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 120. South Korea Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 121. South Korea Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 122. South Korea Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 123. Taiwan Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 124. Taiwan Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 125. Taiwan Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 126. Australia Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 127. Australia Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 128. Australia Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 129. Rest of Asia-Pacific Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 130. Rest of Asia-Pacific Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 131. Rest of Asia-Pacific Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 132. Europe Pharmacovigilance, by Country USD Million (2027-2032)
  • Table 133. Europe Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 134. Europe Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 135. Europe Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 136. Germany Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 137. Germany Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 138. Germany Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 139. France Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 140. France Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 141. France Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 142. Italy Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 143. Italy Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 144. Italy Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 145. United Kingdom Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 146. United Kingdom Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 147. United Kingdom Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 148. Netherlands Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 149. Netherlands Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 150. Netherlands Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 151. Rest of Europe Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 152. Rest of Europe Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 153. Rest of Europe Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 154. MEA Pharmacovigilance, by Country USD Million (2027-2032)
  • Table 155. MEA Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 156. MEA Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 157. MEA Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 158. Middle East Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 159. Middle East Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 160. Middle East Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 161. Africa Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 162. Africa Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 163. Africa Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 164. North America Pharmacovigilance, by Country USD Million (2027-2032)
  • Table 165. North America Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 166. North America Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 167. North America Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 168. United States Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 169. United States Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 170. United States Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 171. Canada Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 172. Canada Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 173. Canada Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 174. Mexico Pharmacovigilance, by End User USD Million (2027-2032)
  • Table 175. Mexico Pharmacovigilance, by Service Provider USD Million (2027-2032)
  • Table 176. Mexico Pharmacovigilance, by Pharmacovigilance Methods USD Million (2027-2032)
  • Table 177. Research Programs/Design for This Report
  • Table 178. Key Data Information from Secondary Sources
  • Table 179. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. South America Pharmacovigilance Share (%), by Country
  • Figure 5. Asia Pacific Pharmacovigilance Share (%), by Country
  • Figure 6. Europe Pharmacovigilance Share (%), by Country
  • Figure 7. MEA Pharmacovigilance Share (%), by Country
  • Figure 8. North America Pharmacovigilance Share (%), by Country
  • Figure 9. Global Pharmacovigilance share by Players 2024 (%)
  • Figure 10. Global Pharmacovigilance share by Players (Top 3) 2024(%)
  • Figure 11. Global Pharmacovigilance share by Players (Top 5) 2024(%)
  • Figure 12. BCG Matrix for key Companies
  • Figure 13. ArisGlobal (United States) Revenue, Net Income and Gross profit
  • Figure 14. ArisGlobal (United States) Revenue: by Geography 2024
  • Figure 15. Ennov Solutions Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Ennov Solutions Inc. (United States) Revenue: by Geography 2024
  • Figure 17. EXTEDO GmbH (United States) Revenue, Net Income and Gross profit
  • Figure 18. EXTEDO GmbH (United States) Revenue: by Geography 2024
  • Figure 19. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis (Switzerland) Revenue: by Geography 2024
  • Figure 21. PARAXEL (United States) Revenue, Net Income and Gross profit
  • Figure 22. PARAXEL (United States) Revenue: by Geography 2024
  • Figure 23. MAKROCARE (India) Revenue, Net Income and Gross profit
  • Figure 24. MAKROCARE (India) Revenue: by Geography 2024
  • Figure 25. Online Business Applications, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Online Business Applications, Inc. (United States) Revenue: by Geography 2024
  • Figure 27. United BioSource Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. United BioSource Corporation (United States) Revenue: by Geography 2024
  • Figure 29. Cmed Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Cmed Group (United Kingdom) Revenue: by Geography 2024
  • Figure 31. Medpace (United States) Revenue, Net Income and Gross profit
  • Figure 32. Medpace (United States) Revenue: by Geography 2024
  • Figure 33. South America Pharmacovigilance Share (%), by Country
  • Figure 34. Asia Pacific Pharmacovigilance Share (%), by Country
  • Figure 35. Europe Pharmacovigilance Share (%), by Country
  • Figure 36. MEA Pharmacovigilance Share (%), by Country
  • Figure 37. North America Pharmacovigilance Share (%), by Country
List of companies from research coverage that are profiled in the study
  • ArisGlobal (United States)
  • Ennov Solutions Inc. (United States)
  • EXTEDO GmbH (United States)
  • Novartis (Switzerland)
  • PARAXEL (United States)
  • MAKROCARE (India)
  • Online Business Applications, Inc. (United States)
  • United BioSource Corporation (United States)
  • Cmed Group (United Kingdom)
  • Medpace (United States)
Additional players considered in the study are as follows:
Sarjen Systems Pvt. Ltd (India) , Sparta Systems, Inc. (United States) , Covance (United States)
Select User Access Type

Key Highlights of Report


Mar 2022 234 Pages 71 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pharmacovigilance research Quantitative research analysis
Global Pharmacovigilance research Qualitative Industry Analysis
Global Pharmacovigilance research Quantitative research analysis
Global Pharmacovigilance research Qualitative Industry Analysis
Global Pharmacovigilance research Quantitative research analysis
Global Pharmacovigilance research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as ArisGlobal (United States), Ennov Solutions Inc. (United States), EXTEDO GmbH (United States), Novartis (Switzerland), PARAXEL (United States), MAKROCARE (India), Online Business Applications, Inc. (United States), United BioSource Corporation (United States), Cmed Group (United Kingdom) and Medpace (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Emergence of Drug Safety and Pharmacovigilance Software " is seen as one of major influencing trends for Pharmacovigilance Market during projected period 2024-2032.
The Pharmacovigilance market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Pharmacovigilance research Report?

Have a Query? Click Here

Other Related Reports

Laser Therapy Caps Comprehensive Study by Type (Caps, Helmets), Application (Hair Loss Treatment, Hair Regrowth), Distribution Channel (Pharmacy Stores, E-commerce, Others) Players and Region - Globa...
$ 3500
Animal Health Care Comprehensive Study by Type (Companion Animals, Farm Animals), Application (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Online Pharmacies), Distribution Cha...
$ 3450
Bio Simulation Comprehensive Study by Type (Software {Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Design Software,...
$ 3750
Healthcare Payer BPO Comprehensive Study by Application (Large hospitals, Middle hospitals, Pharmacy, Insurance companies), Service (Claims Processing Services, Member Services, HR Services, Finance ...
$ 3500
Online Medical Comprehensive Study by Medical Conditions (Counseling, Psychiatry, Behavioural Health, Dermatology, Others), Services (Online Pharmacy, Remote Consultations, Medical Files Assessment, ...
$ 3750
Digital Fitness Comprehensive Study by Type (Hand Wear, Leg Wear, Head Wear, Others), Application (Commercial, Household), Device types (Smartwatch, Wristband, Smart Clothing, Smart Shoes, Bike Compu...
$ 3800
Laser Therapy Caps Comprehensive Study by Type (Caps, Helmets), Application (Hair Loss Treatment, Hair Regrowth), Distribution Channel (Pharmacy Stores, E-commerce, Others) Players and Region - Globa...
$ 3500
Animal Health Care Comprehensive Study by Type (Companion Animals, Farm Animals), Application (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Online Pharmacies), Distribution Cha...
$ 3450
Bio Simulation Comprehensive Study by Type (Software {Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Design Software,...
$ 3750
Healthcare Payer BPO Comprehensive Study by Application (Large hospitals, Middle hospitals, Pharmacy, Insurance companies), Service (Claims Processing Services, Member Services, HR Services, Finance ...
$ 3500
Online Medical Comprehensive Study by Medical Conditions (Counseling, Psychiatry, Behavioural Health, Dermatology, Others), Services (Online Pharmacy, Remote Consultations, Medical Files Assessment, ...
$ 3750
Digital Fitness Comprehensive Study by Type (Hand Wear, Leg Wear, Head Wear, Others), Application (Commercial, Household), Device types (Smartwatch, Wristband, Smart Clothing, Smart Shoes, Bike Compu...
$ 3800
Laser Therapy Caps Comprehensive Study by Type (Caps, Helmets), Application (Hair Loss Treatment, Hair Regrowth), Distribution Channel (Pharmacy Stores, E-commerce, Others) Players and Region - Globa...
$ 3500
Animal Health Care Comprehensive Study by Type (Companion Animals, Farm Animals), Application (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Online Pharmacies), Distribution Cha...
$ 3450
Bio Simulation Comprehensive Study by Type (Software {Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and Simulation Software, Trial Design Software,...
$ 3750
Healthcare Payer BPO Comprehensive Study by Application (Large hospitals, Middle hospitals, Pharmacy, Insurance companies), Service (Claims Processing Services, Member Services, HR Services, Finance ...
$ 3500